Ibere Pharmaceuticals Total Liabilities

Ibere Pharmaceuticals's total liabilities stands at $5.9M as of September 2022. That compares with $12M in the prior-year period — down 51.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Ibere Pharmaceuticals reported $5.9M in total liabilities versus $12M a year earlier — a 51.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $12M in the prior-year period — down 51.1% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Ibere Pharmaceuticals's total liabilities evolved across reporting periods, while the comparison chart places IBER next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.